Expansion of the Consumer Healthcare Business Centered on Hepalyse

「The Hepalyse range continued to perform well, centered on the pharmaceutical Hepalyse range, partly due to the effects of active advertising and promotional activities. Meanwhile, the Chondroitin range and the WithOne range of plant-based laxatives reported lower sales due to the impact of competing products.」

「Sales of the Hepalyse and Chondroitin ranges and the WithOne range of plant-based laxatives increased, partly due to the effects of investment in advertising and promotional activities. Meanwhile, sales of some products, including the Prevalin and Masdent ranges, declined due partly to the impact of competing products.」

「Sales of the Hepalyse W range for convenience stores increased, partly due to the contribution of Hepalyse W Shine, a new product launched in October 2024 as a soft drink. The pharmaceutical Hepalyse range also performed well, as marketing it for relief from fatigue proved effective. Sales of the WithOne range of plant-based laxatives and the Prevalin range of treatments for skin conditions also increased.」

「Sales of both the pharmaceutical Hepalyse range and the Hepalyse W range for convenience stores increased. The WithOne range of plant-based laxatives and the Prevalin range of treatments for skin conditions, which launched the new products Prevalin Alpha Quick Ointment and Prevalin Alpha Quick Cream in the previous fiscal year, also remained firm. Sales of the Chondroitin range were broadly in line with the previous fiscal year. Shipments of Hepalyse W Shine, a new product in the Hepalyse W series scheduled for launch in October 2024, began in September.」

「In the consumer healthcare business, we will focus on advertising and sales promotion activities that communicate product characteristics more clearly, with the aim of expanding sales of the Hepalyse, Chondroitin and WithOne ranges, our core product lines. We will also expand the business by increasing sales of numerous product lines, including the Iona basic skincare series, the Masdent range of medicated toothpaste, western herbal products including Prefemin, the only PMS treatment available in Japan as an OTC drug, and the Prevalin range of treatments for skin conditions.」

「Sales of both the pharmaceutical Hepalyse range and the Hepalyse W range for convenience stores increased due to the easing of behavioral restrictions implemented in response to COVID-19 and the associated recovery in foot traffic. Sales of the Chondroitin range also performed well, partly as a result of active investment in advertising and promotional activities. Sales of the western herbal products, including Prefemin, a treatment for premenstrual syndrome (PMS) that transitioned to a Class 2 OTC drug in April 2023, and the Masdent range of medicated toothpaste for periodontal disease and bad breath also increased.」

「Sales of both the pharmaceutical Hepalyse range and the Hepalyse W range for convenience stores increased due to the easing of behavioral restrictions implemented in response to COVID-19 and the associated recovery in foot traffic.」

「In the consumer healthcare business, we will focus on sales promotion activities aligned with changes in consumer behavior and needs, as well as advertising and promotional activities that communicate product characteristics more clearly, to expand sales of the Hepalyse, Chondroitin and WithOne ranges, our core product lines. We will also focus on developing new sales channels and fostering product lines following our core products.」

「Although the Hepalyse range remained affected by the spread of COVID-19 and the sharp decline in inbound demand, sales increased significantly as both the pharmaceutical Hepalyse range and the Hepalyse W range for convenience stores entered a recovery trend. The Chondroitin range also remained firm, partly as a result of active investment in advertising and promotional activities. Meanwhile, sales of the WithOne range of plant-based laxatives declined due partly to the impact of competing products.」

「Although the Hepalyse range remained affected by the spread of COVID-19 and the sharp decline in inbound demand, sales increased significantly as both the pharmaceutical Hepalyse range and the Hepalyse W range for convenience stores grew substantially.」

「Although the Hepalyse range remained affected by the spread of COVID-19 and the sharp decline in inbound demand, sales increased significantly as both the pharmaceutical Hepalyse range and the Hepalyse W range for convenience stores grew substantially.」

「For the Hepalyse range, whose sales declined significantly in the previous fiscal year, sales increased due to growth in the pharmaceutical range and the Hepalyse W range for convenience stores turning to recovery in the third quarter. Meanwhile, sales of the Chondroitin range, the WithOne range of plant-based laxatives and hygiene products, including disinfectants, declined due partly to the impact of competing products.」

「For the Hepalyse range, whose sales declined significantly in the previous fiscal year, the pharmaceutical Hepalyse range was on a recovery trend due to growth in solid dosage forms, but the Hepalyse W range for convenience stores remained weak, limiting the recovery in sales. The Chondroitin range remained firm, partly as a result of active investment in advertising and promotional activities. Meanwhile, sales of the WithOne range of plant-based laxatives and hygiene products, including disinfectants, declined due partly to the impact of competing products.」

「The Hepalyse range, whose sales declined in the previous fiscal year, remains strongly affected by restrictions on going out and declining inbound demand, but both the pharmaceutical Hepalyse range for drugstores, pharmacies and dispensing pharmacies and the Hepalyse W range for convenience stores are on a recovery trend. Sales of the Chondroitin range also increased, partly as a result of active investment in advertising and promotional activities. Meanwhile, sales of the WithOne range of plant-based laxatives and hygiene products, including disinfectants, declined due partly to the impact of competing products.」

「Sales of hygiene products, including disinfectants, increased. However, restrictions on going out associated with the spread of COVID-19, declining inbound demand and intensifying competition with other products caused the business as a whole to struggle, including its core products, the Hepalyse and Chondroitin ranges.」

「Sales of the WithOne range of plant-based laxatives and hygiene products, including disinfectants, increased. However, restrictions on going out associated with the spread of COVID-19 and intensifying competition with other products caused the business as a whole to struggle, including its core products, the Hepalyse and Chondroitin ranges. As a result, sales in the business were ¥5,730 million, down 19.1% year on year, and operating profit was ¥1,061 million, down 40.1%.」

「For the Hepalyse range, tablets in the pharmaceutical category, including Hepalyse Plus II, remained firm. However, in addition to intensifying competition with other bottled products in the convenience store market, sales of the Hepalyse W range fell sharply in the fourth quarter due to restrictions on going out associated with the spread of COVID-19, causing overall sales to turn lower.」

「The Hepalyse range, a core product line, remained flat despite active advertising and promotional activities, due partly to the effects of intensifying market competition. For the Chondroitin range, the company continued sales activities emphasizing efficacy, safety and high quality as pharmaceuticals and clearly differentiating the products from health foods, resulting in steady sales growth. The WithOne range of plant-based laxatives also remained firm. However, the subsidiary's weak supplement business affected the results, and sales in this business were ¥22,557 million, down 2.1% year on year.」

「The Hepalyse range, a core product line, continued to achieve sales growth as a result of active advertising and promotional activities, including television commercials, and efforts to raise product awareness. In June 2019, Hepalyse W Jelly was rolled out nationwide, strengthening the product lineup. For the Chondroitin range, the company continued sales activities emphasizing efficacy, safety and high quality as pharmaceuticals and clearly differentiating the products from health foods, resulting in sales growth. The WithOne range of plant-based laxatives also remained firm.」

「The Hepalyse range, a core product line, continued to achieve sales growth as a result of active advertising and promotional activities, including television commercials, and efforts to raise product awareness. In June 2019, Hepalyse W Jelly was rolled out nationwide, strengthening the product lineup. For the Chondroitin range, sales remained firm as a result of sales activities emphasizing efficacy, safety and high quality as pharmaceuticals and clearly differentiating the products from health foods. Meanwhile, some products, including the WithOne range, struggled amid intensifying market competition.」

「During the consolidated fiscal year, we launched 3 new products, Hepalyse W Premium Kiwami, Hepalyse Super Rich and Hepalyse W Jelly, strengthening our product lineup. As a result of these sales expansion measures, sales continued to increase.」

「The Hepalyse range, a core product line, continued to achieve sales growth as a result of active advertising and promotional activities, including television commercials, and efforts to raise product awareness. In April 2018, the company launched Hepalyse W Premium Kiwami as the top-tier product in the Hepalyse W series, strengthening its product lineup.」

「Although the Hepalyse range, a core product line, was affected by unfavorable weather and other factors, it continued to achieve sales growth as a result of active advertising and promotional activities, including television commercials, and efforts to raise product awareness. In April 2018, the company launched Hepalyse W Premium Kiwami as the top-tier product in the series, strengthening its product lineup.」

「The Hepalyse and WithOne ranges, both core product lines, continued to achieve sales growth as a result of active advertising and promotional activities, including television commercials, and efforts to raise product awareness.」

「In the consumer healthcare business, we will strengthen our sales organization through the active allocation of management resources, further reinforce the brand strength of core products developed to date, including the Hepalyse, Chondroitin and WithOne ranges, accelerate the development of new sales channels and foster new product lines following the current core products.」

「The Hepalyse and WithOne ranges, both core product lines, continued to achieve sales growth as a result of active advertising and promotional activities, including television commercials, and efforts to raise product awareness.」

「The Hepalyse range, a core product line, continued to achieve sales growth as active advertising and promotional activities, including television commercials, further increased product awareness.」

「The Hepalyse range, a core product line, continued to achieve sales growth as a result of active advertising and promotional activities, including television commercials, and efforts to raise product awareness. In particular, Hepalyse W Premium, a new product for convenience stores launched in March last year, and Hepalyse King Plus and Hepalyse King EX, mini bottled products for drugstores launched in October last year and classified as Class 2 OTC drugs, made significant contributions to the increase in sales.」

「The Hepalyse range, a core product line, continued to achieve sales growth as a result of active advertising and promotional activities, including television commercials, and efforts to raise product awareness.」

「The Hepalyse range, a core product line, continued to achieve sales growth as a result of active advertising and promotional activities, including television commercials, and efforts to raise product awareness. In particular, Hepalyse W Premium, launched in March 2016 to strengthen the Hepalyse W range for convenience stores, has performed well.」

「We will further expand the Hepalyse range, which is steadily increasing sales, and establish it as a core product line in the business. We will also work to increase sales of the Chondroitin range, the WithOne range and Prefemin, a distinctive western herbal medicine, while enhancing our position in the industry.」